January 6, 2015 10:34 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Celgene Corporation (NASDAQ: CELG) with an Equal-Weight rating and $120.00 price target.In the report, Barclays Capital noted, “The key drivers for Celgene's core Revlimid/Pomalyst/Abraxane franchises are approval for Revlimid in newly diagnosed myeloma in the US/EU and the EU rollout of Abraxane for pancreatic cancer. We believe that this is reflected in the consensus of ~20% revenue growth; when looking at upside potential, it is weighted to 2016, not 2015. Longer term, the Street has been focused on the 2017 outlook and while we're impressed with Celgene's partnered pipeline (Agios, Acceleron, Epizyme, etc.) and phase 2 data for GED-0301 (mongersen) in Crohn's disease, neither should materially alter this outlook. Overall, while fundamentals are solid for Celgene, the upside levers are known and may not begin to play out until 2016 and there are fewer pipeline de-risking events in 2015. Hence, we're initiating coverage with an Equal Weight rating and $120 price target.”Celgene closed on Monday at $11.93.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.